China IOL Reimbursement Landscape — April 2026
A short reference PDF on current reimbursement regimes, VBP anchor prices, and policy developments through Q1 2026.
Over the past twelve months, the Chinese intraocular lens market has settled into three coexisting reimbursement regimes. Winning prices from the 4th national VBP round have become binding payment standards. Enforcement has begun.
We have compiled a short reference PDF that captures the current state of the landscape in three pages: the four-sentence summary we would take to an HQ meeting, the 4th VBP anchor price table, and the four policy developments of the past twelve months.
The PDF is free to download below. No sign-up required to read; subscription is open if you want to follow ongoing work on this topic.
— OphthalLogix Intelligence Team
This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.